Neurizon Therapeutics (ASX: NUZ) has announced encouraging outcomes from an independent study assessing its neuroprotective ...

Neurizon Therapeutics Ltd (ASX:NUZ) has yielded positive results from an independent study – conducted in collaboration with ...

NUZ-001 has shown it promotes healthy and viable brain tissues, potentially demonstrating its use to treat Alzheimer’s and ...

Mach 7 and Universal Biosensors have announced their CEOs will depart, while changes at the top are likely at other biotechs.

Stockhead’s Tylah Tully chats with Neurizon Therapeutics (ASX:NUZ) managing director Michael Thurn about the company's goal ...

NUZ-001 slowed respiratory declines in ALS patients in a Phase 1 trial, and Neurizon is working to ready it for the HEALEY ...

Neurizon Therapeutics' (ASX:NUZ) lead drug candidate has demonstrated positive results in the latest round of testing with ...

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Neurizon Therapeutics Limited (NUZ). However, you won't necessarily see their names in the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Several ASX healthcare companies are leading the charge in finding new treatments for complex neurological disorders.

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, Tylah Tully gives the ...

Financial Health for Neurizon Therapeutics is determined by ranking the company on over 100 factors against companies in the Healthcare sector and operating in Developed economic markets. Loading view ...